Lymphoma

Non-Hodgkin's Lymphoma

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi- 
    dimensionally measurable lesion <: 1.5 cm.
  • Must have had at least one prior anti-cancer treatment

SCRI HEMREF-34

An Open-Label, Phase lb Study of IPl-145 in
Combination with Bendamustlne, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia cancer treatment.

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • Subjects must have rituxlmab - refractory disease
  • Must have at least one bi-dimensionally measurable lesion > 1.5 cm.

SCRI LYM-87

A Phase 2 Study of IPl-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma

 

 

 

 

  

Criteria to qualify for study: Drug used in study:
  • —Bidimensionally measurable disease of at least 2.0 cm
  • —Patient must have received 2 prior therapies
  • —PLT must be at least 100
  • —ANC must be at least 1000
  • —Hemoglobin must be at least 8

SCRI  HEMREF 37

A Phase 1 Study  of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminiase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies

 

 

 

 

 

   

Criteria to qualify for study: Drug used in study:
  • Bidimensionally measurable disease of at least 1.5 cm
  • Patients who have been treated with
    single agent rituximab or corticosteroids
    as monotherapy are excluded.
  • No ALCL
  • PLT must be >50, ANC must be >1000
  • Patient does not have to be CDE30 positive

SGN35-012  CBCl-223

A Phase 2 study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma (NHL)

(T-Cell ARM Closed)

 

 

 

 

 

  

 


Hodgkin's Lymphoma

Criteria to qualify for study: Drug used in study:
  • ŸBi-dimensionally measurable disease of 
    at least 1.5 cm 
  • Patients cannot have received more than 1 prior chemotherapy regimen for HL
  • Must be in 1st relapse

SGN35-016

A Phase 1/2 Single-Arm, Open-Label Study to Evaluate The Safety and Efficacy of Brentuximab Vedotin in combination with  Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)

 

 

 

 

 

 

Criteria to qualify for study: Drug used in study:
  • —Hemoblobin A1C must be ≤ 6.4% 
  • Patient must  be tested for and be negative for HIV, Hep B & C 
  • PLT must be at least 75
  • ANC must be at least 1000
  • Creatinine ≤ 1.5 x ULN or Cr Cl ≥ 50 ml/min

SCRI  LYM 90

 A Phase 1 Study of CPI-0610, a Small Melecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma